Preoperative Fibrinogen and Hematological Indexes in the Differential Diagnosis of Idiopathic Granulomatous Mastitis and Breast Cancer

Mehmet Velidedeoglu, Berrin Papila Kundaktepe, Hulya Aksan, Hafize Uzun, Mehmet Velidedeoglu, Berrin Papila Kundaktepe, Hulya Aksan, Hafize Uzun

Abstract

Background and Aim: Studies on hematological parameters in the differential diagnosis of idiopathic granulomatous mastitis (IGM) and breast cancer (BC) are limited. This study investigated whether preoperative fibrinogen and hematological indexes can be used in the differential diagnosis of patients with IGM and early-onset BC. Methods: Fifty patients with BC, 55 patients with IGM, and 50 healthy volunteer women were included in the study. Results: There was a statistically significant difference between the IGM and the BC with respect to fibrinogen, fibrinogen/albumin (Fib/Alb) ratio, C-reactive protein (CRP), white blood cells (WBC), neutrophils, neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and monocyte values. When fibrinogen (p < 0.001), the Fib/Alb ratio (p < 0.001), CRP (p < 0.001), WBC (p < 0.001), neutrophil (p < 0.001), NLR (p < 0.001), monocyte (p = 0.008), and 2-hour sedimentation rate (p < 0.001) were compared between the groups, the highest levels were found in the IGM group. There was a negative relationship between CRP and albumin, and a positive relationship was observed between CRP and WBC, NLR, PLR, and 2-h sedimentation rate. CRP had the highest sensitivity (95%), whereas the Fib/Alb ratio (86%) had the highest specificity. Patients with recurrent IGM had increased fibrinogen, Fib/Alb, CRP, neutrophils, NLR, and 2-h erythrocyte sedimentation rate (ESR) and decreased lymphocyte levels compared to non-recurrent patients. Conclusions: Preoperative CRP, albumin, fibrinogen, Fib/Alb, WBC, neutrophil, NLR, monocyte, and 2-h ESR have considerable potential to be early and sensitive biomarkers of IGM caused by inflammation compared to BC. These parameters also have a significant effect on the recurrence of the disease, suggesting their potential as a practical guide for the differential diagnosis of BC from IGM.

Keywords: CRP; albumin; breast cancer; fibrinogen; idiopathic granulomatous mastitis; neutrophil–lymphocyte ratio; recurrence.

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
ROC analysis of parameters for breast cancer and IGM.
Figure 2
Figure 2
ROC analysis of parameters for patients with non-recurrent and recurrent IGM.

References

    1. Omranipour R., Vasigh M. Mastitis, breast abscess, and granulomatous mastitis. Adv. Exp. Med. Biol. 2020;1252:53–61.
    1. Kessler E., Wolloch Y. Granulomatous mastitis: A lesion clinically simulating carcinoma. Am. J. Clin. Pathol. 1972;58:642–646. doi: 10.1093/ajcp/58.6.642.
    1. Hovanessian Larsen L.J., Peyvandi B., Klipfel N., Grant E., Iyengar G. Granulomatous lobular mastitis: Imaging, diagnosis, and treatment. Am. J. Roentgenol. 2009;193:574–581. doi: 10.2214/AJR.08.1528.
    1. Pandey T.S., Mackinnon J.C., Bressler L., Millar A., Marcus E.E., Ganschow P.S. Idiopathic granulomatous Mastitis—A prospective study of 49 women and treatment outcomes with steroid therapy. Breast J. 2014;20:258–266. doi: 10.1111/tbj.12263.
    1. Mathew M., Siwawa P., Misra S. Idiopathic granulomatous mastitis: An inflammatory breast condition with review of the literature. BMJ Case Rep. 2015;2015:bcr2014208086. doi: 10.1136/bcr-2014-208086.
    1. World Health Organization International Agency for Research on Cancer The Global Cancer Observatory. 2018 Statistics. [(accessed on 17 January 2019)]; Available online: .
    1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2020. CA Cancer J. Clin. 2020;70:7–30. doi: 10.3322/caac.21590.
    1. de Gelder R., Heijnsdijk E.A., Fracheboud J., Draisma G., de Koning H.J. The effects of population-based mammography screening starting between age 40 and 50 in the presence of adjuvant systemic therapy. Int. J. Cancer. 2015;137:165–172. doi: 10.1002/ijc.29364.
    1. Munoz D., Near A.M., van Ravesteyn N.T., Lee S.J., Schechter C.B., Alagoz O., Berry D.A., Burnside E.S., Chang Y., Chisholm G., et al. Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality. J. Natl. Cancer Inst. 2014;106:dju289. doi: 10.1093/jnci/dju289.
    1. Tabár L., Dean P.B., Chen T.H., Yen A.M., Chen S.L., Fann J.C., Chiu S.Y., Ku M.M., Wu W.Y., Hsu C.Y., et al. The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening. Cancer. 2019;125:515–523. doi: 10.1002/cncr.31840.
    1. Coussens L.M., Werb Z. Inflammation and cancer. Nature. 2002;420:860–867. doi: 10.1038/nature01322.
    1. Dranoff G. Immune recognition and tumor protection. Curr. Opin. Immunol. 2002;14:161–164. doi: 10.1016/S0952-7915(02)00315-1.
    1. Pardoll D.M. Spinning molecular immunology into successful immunotherapy. Nat. Rev. Immunol. 2002;2:227–238. doi: 10.1038/nri774.
    1. Balkwill F., Mantovani A. Inflammation and cancer: Back to Virchow? Lancet. 2001;357:539–545. doi: 10.1016/S0140-6736(00)04046-0.
    1. Sun J., Chen X., Gao P., Song Y., Huang X., Yang Y., Zhao J., Ma B., Gao X., Wang Z. Can the neutrophil to lymphocyte ratio be used to determine gastric cancer treatment outcomes? A systematic review and meta-analysis. Dis. Markers. 2016;2016:7862469. doi: 10.1155/2016/7862469.
    1. Zou Z.Y., Liu H.L., Ning N., Li S.Y., Du X.H., Li R. Clinical significance of pre-operative neutrophil lymphocyte ratio and platelet lymphocyte ratio as prognostic factors for patients with colorectal cancer. Oncol. Lett. 2016;11:2241–2248. doi: 10.3892/ol.2016.4216.
    1. Tang L.Q., Chen Q.Y., Guo S.S., Chen W.H., Li C.F., Zhang L., Lai X.P., He Y., Xu Y.X., Hu D.P., et al. The impact of plasma Epstein-Barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: An observational study. Br. J. Cancer. 2014;111:1102–1111. doi: 10.1038/bjc.2014.393.
    1. Fu Y.P., Ni X.C., Yi Y., Cai X.Y., He H.W., Wang J.X., Lu Z.F., Han X., Cao Y., Zhou J., et al. A Novel and validated Inflammation-Based Score (IBS) predicts survival in patients with hepatocellular carcinoma following curative surgical resection: A STROBE-compliant article. Medicine. 2016;95:e2784. doi: 10.1097/MD.0000000000002784.
    1. Wei B., Yao M., Xing C., Wang W., Yao J., Hong Y., Liu Y., Fu P. The neutrophil lymphocyte ratio is associated with breast cancer prognosis: An updated systematic review and meta-analysis. OncoTargets Ther. 2016;9:5567–5575. doi: 10.2147/OTT.S108419.
    1. Krenn-Pilko S., Langsenlehner U., Thurner E.M., Stojakovic T., Pichler M., Gerger A., Kapp K.S., Langsenlehner T. The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Br. J. Cancer. 2014;110:2524–2530. doi: 10.1038/bjc.2014.163.
    1. Wang D., Duan L., Tu Z., Yan F., Zhang C., Li X., Cao Y., Wen H. The Glasgow prognostic score predicts response to chemotherapy in patients with metastatic breast cancer. Chemotherapy. 2016;614:217–222. doi: 10.1159/000443367.
    1. Küçük E., Kocayiğit İ., Günel C., Düzenli H. Neutrophil-to-lymphocyte ratio in occlusive vascular diseases: The literature review of the past 10 years. World J. Emerg. Med. 2016;7:165–172. doi: 10.5847/wjem.j.1920-8642.2016.03.001.
    1. Templeton A.J., McNamara M.G., Šeruga B., Vera-Badillo F.E., Aneja P., Ocaña A., Leibowitz-Amit R., Sonpavde G., Knox J.J., Tran B., et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. J. Natl. Cancer Inst. 2014;106:dju124. doi: 10.1093/jnci/dju124.
    1. Akalın Ç., Altaş H., Çelik M.A. White blood count can be a practical guide for the differential diagnosis of breast abscess and idiopathic granulomatous mastitis. Cureus. 2020;12:e10468. doi: 10.7759/cureus.10468.
    1. Sicking I., Edlund K., Wesbuer E., Weyer V., Battista M.J., Lebrecht A., Solbach C., Grinberg M., Lotz J., Hoffmann G., et al. Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients. PLoS ONE. 2014;9:e111306. doi: 10.1371/journal.pone.0111306.
    1. Cho Y.A., Sung M.K., Yeon J.Y., Ro J., Kim J. Prognostic role of interleukin-6, interleukin-8, and leptin levels according to breast cancer subtype. Cancer Res. Treat. 2013;45:210–219. doi: 10.4143/crt.2013.45.3.210.
    1. Tripsianis G., Papadopoulou E., Anagnostopoulos K., Botaitis S., Katotomichelakis M., Romanidis K., Kontomanolis E., Tentes I., Kortsaris A. Coexpression of IL-6 and TNF-α: Prognostic significance on breast cancer outcome. Neoplasma. 2014;61:205–212. doi: 10.4149/neo_2014_026.
    1. Lowe G.D. The relationship between infection, inflammation, and cardiovascular disease: An overview. Ann. Periodontol. 2001;6:1–8. doi: 10.1902/annals.2001.6.1.1.
    1. Erdogan S., Yilmaz F.M., Yazici O., Yozgat A., Sezer S., Ozdemir N., Uysal S., Purnak T., Sendur M.A., Ozaslan E. Inflammation and chemerin in colorectal cancer. Tumour Biol. 2016;37:6337–6342. doi: 10.1007/s13277-015-4483-y.
    1. Casamassima A., Picciariello M., Quaranta M., Berardino R., Ranieri C., Paradiso A., Lorusso V., Guida M. C-reactive protein: A biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J. Urol. 2005;173:52–55. doi: 10.1097/01.ju.0000146713.50673.e5.
    1. Guo F., Liu J., Wang C., Liu N., Lu P. Fibrinogen, fibrin, and FDP induce C-reactive protein generation in rat vascular smooth muscle cells: Pro-inflammatory effect on atherosclerosis. Biochem. Biophys. Res. Commun. 2009;390:942–946. doi: 10.1016/j.bbrc.2009.10.082.
    1. Abou-Raya S., Abou-Raya A., Naim A., Abuelkheir H. Rheumatoid arthritis, periodontal disease and coronary artery disease. Clin. Rheumatol. 2008;27:421–427. doi: 10.1007/s10067-007-0714-y.
    1. Reinhart W.H. Blood sedimentation—A simple and useful test? Schweiz. Med. Wochenschr. 1988;118:839–844.
    1. Kilicarslan A., Uysal A., Roach E.C. Acute phase reactants. Acta Medica. 2013;2:2–7.
    1. Zheng Y., Wu C., Yan H., Chen S. Prognostic value of combined preoperative fibrinogen-albumin ratio and platelet-lymphocyte ratio score in patients with breast cancer: A prognostic nomogram study. Clin. Chim. Acta. 2020;506:110–121. doi: 10.1016/j.cca.2020.03.011.
    1. Destek S., Gul V.O., Ahioglu S. A variety of gene polymorphisms associated with idiopathic granulomatous mastitis. J. Surg. Case Rep. 2016;2016:rjw156. doi: 10.1093/jscr/rjw156.
    1. Yigitbasi M.R., Guntas G., Atak T., Sonmez C., Yalman H., Uzun H. The role of interleukin-33 as an inflammatory marker in differential diagnosis of idiopathic granulomatous mastitis and breast cancer. J. Invest. Surg. 2017;30:272–276. doi: 10.1080/08941939.2016.1240270.
    1. Aksan H., Kundaktepe B.P., Sayili U., Velidedeoglu M., Simsek G., Koksal S., Gelisgen R., Yaylim I., Uzun H. Circulating miR-155, let-7c, miR-21, and PTEN levels in differential diagnosis and prognosis of idiopathic granulomatous mastitis and breast cancer. Biofactors. 2020;46:955–962. doi: 10.1002/biof.1676.
    1. Jacquin-Porretaz C., Devalland C., Delapparent T., Nardin C., Dupond A.S. Idiopathic granulomatous mastitis associated with erythema nodosum. Ann. Dermatol. Venereol. 2019;146:571–576. doi: 10.1016/j.annder.2019.04.023.
    1. O’Byrne K.J., Dalgleish A.G. Chronic immune activation and inflammation as the cause of malignancy. Br. J. Cancer. 2001;85:473–483. doi: 10.1054/bjoc.2001.1943.
    1. Ikeda M., Furukawa H., Imamura H., Shimizu J., Ishida H., Masutani S., Tatsuta M., Satomi T. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann. Surg. Oncol. 2002;9:287–291. doi: 10.1007/BF02573067.
    1. Çetinkaya Ö.A., Çelik S.U., Terzioğlu S.G., Eroğlu A. The predictive value of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio in patients with recurrent idiopathic granulomatous mastitis. Eur. J. Breast Health. 2020;16:61–65. doi: 10.5152/ejbh.2019.5187.
    1. Kargin S., Turan E., Esen H.H. Role of pre-treatment neutrophil-lymphocyte ratio in the prediction of recurrences after granulomatous mastitis treatment. Turk. Klin. J. Med Sci. 2020;40:46–51.
    1. Yau F.M., Macadam S.A., Kuusk U., Nimmo M., Van Laeken N. The surgical management of granulomatous mastitis. Ann. Plast. Surg. 2010;64:9–16. doi: 10.1097/SAP.0b013e3181a20cae.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever